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ABSTRACT
Purpose Systematic comparison of analysis methods of clini-
cal microdialysis data for impact on target-site drug exposure
and response.
Methods 39 individuals received a 500 mg levofloxacin
short-term infusion followed by 24-h dense sampling in plas-
ma and microdialysate collection in interstitial space fluid
(ISF). ISF concentrations were leveraged using non-
compartmental (NCA) and compartmental analysis (CA) via
(ii) relative recovery correction at midpoint of the collection
interval (midpoint-NCA, midpoint-CA) and (ii) dialysate-
based integrals of time (integral-CA). Exposure and adequacy
of community-acquired pneumonia (CAP) therapy via
pharmacokinetic/pharmacodynamic target-attainment
(PTA) analysis were compared between approaches.
Results Individual AUCISF estimates strongly varied for
midpoint-NCA and midpoint-CA (≥52.3%CV) versus
integral-CA (≤32.9%CV) owing to separation of variability
in PK parameters (midpoint-CA= 46.5%–143%CVPK, inte-
gral-CA = 26.4%–72.6%CVPK) from recovery-related vari-
ability only in integral-CA (41.0%–50.3%CVrecovery). This
also led to increased variability of AUCplasma for midpoint-
CA (56.0%CV) versus midpoint-NCA and integral-CA
(≤33.0%CV), and inaccuracy of predictive model perfor-
mance of midpoint-CA in plasma (visual predictive check).
PTA analysis translated into 33% of evaluated patient cases
being at risk of incorrectly rejecting recommended dosing
regimens at CAP-related epidemiological cut-off values.
Conclusions Integral-CA provedmost appropriate to charac-
terise clinical pharmacokinetics- and microdialysis-related
variability. Employing this knowledge will improve the under-
standing of drug target-site PK for therapeutic decision-
making.
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ABBREVIATIONS
AUC0–8 Area under the concentration-time curve
from 0 to 8 h
CAP Community-acquired pneumonia
CFR Cumulative fraction of response
CLCR Creatinine clearance
Cmax Maximum concentration
ECOFF Epidemiological cut-off value
EUCAST European Committee on Antimicrobial
Susceptibility Testing
fAUC0–8 Area under the unbound concentration-time
curve from 0 to 8 h
fAUC0–24 Area under the unbound concentration-time
curve from 0 to 24 h
Integral-CA Dialysate-based integral compartmental
analysis
ISF Interstitial space fluid
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PTA Probability of target attainment
RSE Relative standard error
RR Relative recovery
V1 Central volume of distribution
Vtot Total volume of distribution
INTRODUCTION
Clinical pharmacokinetic (PK) studies typically determine
drug concentrations in plasma, although this is rarely the tar-
get site of the drug. In bacterial infections, the pathogens are
mainly found in the interstitial space fluid (ISF), i.e. represent-
ing the target site for antibiotics [1]. For several antibiotics,
considerable PK differences have been observed between
plasma and interstitial fluid [2, 3]. Consequently, the recent
European Medical Agency guideline for the development of
new antibacterial drugs recommended sampling at the target
site [4], mentioning the use of microdialysis, a minimally in-
vasive sampling technique that allows continuous measure-
ments of drug concentrations in the ISF over time [5].
In short, the microdialysis system consists of a catheter with
a semipermeable membrane connected to a microdialysis
pump (inlet) and to amicrovial (outlet) via tubings for dialysate
sampling over a collection interval [6]. During microdialysis
investigations, perfusate is pumped through the catheter
inserted in the ISF of the tissue of interest. The semipermeable
membrane at the tip of the catheter allows bidirectional flow
of unbound drug molecules along the concentration gradient.
After drug intake by a patient, unbound drug molecules pres-
ent in ISF permeate into the catheter and are transported into
the microvial. Due to the constant flow, the drug concentra-
tion in themicrodialysate will be lower than in ISF. Hence, the
measured microdialysate concentration has to be converted
by a transformation factor, the relative recovery (RR),
obtained using catheter calibration methods. Here, the meth-
od of choice in humans is retrodialysis [7], in which retroper-
fusate is spiked with the drug of interest. RR for the loss of
drug from the retroperfusate in the catheter via themembrane




with Cretrodialysate and Cretroperfusate representing retrodialysate
and retroperfusate concentration, respectively.
Assuming equal permeation processes in both directions,
RR can be used to convert the measured dialysate concentra-
tion into ISF concentration, by dividing the microdialysate
concentration by RR.
Clinical microdialysis data are commonly evaluated via
dialysate-corrected mid-interval based noncompartmental
analysis (midpoint-NCA, in the following termed NCA)
[8–10] or via nonlinear mixed-effects (NLME) modelling
employing dialysate-corrected mid-interval compartmental
analysis (midpoint-CA) [11–13]. Both approaches correct
the microdialysate concentrations by RR prior to data analysis.
This has two important limitations: Data transformation prior
to analysis results in loss of information on variability associated
with RR and microdialysate concentrations are allocated to a
specific time point despite originating from a time interval.
To overcome these limitations, Tunblad et al. developed a
dialysate-based integral NLME compartmental analysis
(Integral-CA) approach for microdialysis data of morphine/
probenecid administration in a small number of rats [14].
Integral-CA integrates all collected drug concentration data
(i.e. -if collected- plasma concentrations, retroperfusate, retro-
dialysate, and microdialysate) simultaneously in one compre-
hensive model-based analysis. Despite these theoretical bene-
fits of integral-CA over NCA and midpoint-CA, no difference
in selected model structure or PK parameter estimates could
be shown [14]. Consequently it remains difficult to justify the
selection of the more complex and computationally expensive
integral-CA over midpoint-CA or NCA for the analysis of
clinical microdialysis data. Despite this knowledge gap, recent-
ly integral-CA has been regularly employed in analyses of
clinical microdialysis data alongside NCA and midpoint-CA
[2, 15, 16]. Thus, a quantitative comparison of NCA,
midpoint-CA and integral-CA based on a compound with
well-characterised PK and availability of clinical target-site
concentration data is required.
Levofloxacin, a broad-spectrum fluoroquinolone, encom-
passing both Gram-negative and Gram-positive organisms
including anaerobic bacteria [17], represents such a clinically
well-characterised drug, which in addition showed no binding
tomicrodialysis tubing or probes in vitro [18]. It is used for the
treatment of various infections, such as community-acquired
pneumonia (CAP) [19–21], skin and soft tissue infections, uri-
nary tract infections, and acute exacerbation of chronic bron-
chitis and sinusitis [22]. Levofloxacin is a moderately lipophil-
ic drug and hence exerts its antibiotic activity in bacteria typ-
ically residing in the ISF. It has been shown that the most
relevant predictor of fluoroquinolone efficacy in clinical set-
tings is the 24-h area under the unbound drug concentration-
time curve (fAUC0–24) divided by the minimum inhibitory
concentration (MIC) [23] for different bacteria strains.
The objectives of this study were to quantitatively compare
(1) levofloxacin exposure calculated via NCA, midpoint-CA
and integral-CA in plasma and at target site, and (2) the PK/
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pharmacodynamic (PD) evaluation of current dosing regi-
mens evaluated via midpoint-CA and integral-CA.
Ultimately, the aim was to derive recommendations for
target-site data analysis integrating all available measurements
obtained in microdialysis studies.
METHODS
Model comparison was based on PK measurements of four
single centre, clinical microdialysis studies in patients with soft
tissue infections (n = 8) [24], patients receiving coronary by-
pass surgery (n = 12) [10], patients undergoing elective lung
surgery (n = 5) [25] as well as healthy volunteers (n = 7) and
septic patients (n = 7, Table I) [26]. All individuals received
500 mg levofloxacin (Tavanic®; SANOFI, Frankfurt/Main,
Germany) administered as a single intravenous infusion over
30min, except for the lung surgery patients, who received a 1-
h infusion of the same dose. Blood samples and microdialysis
data (20–120 min collection intervals, with ≤30 min intervals
for the first 2 h after drug administration and ≥60 min inter-
vals for the rest of the collection time) were collected up to 24 h
after the start of the infusion [10, 24–26]. In all participants,
microdialysis catheters were inserted into the ISF of subcuta-
neous adipose tissue of the thigh and skeletal muscle of the
thigh and perfused with Ringer’s solution. Additionally, in soft
tissue infection patients, catheters were placed in ISF of
infected and noninfected subcutaneous adipose tissue.
Retrodialyses were carried out for 30 min [10, 24–26],
yielding a single sample per catheter. Plasma, microdial-
ysis and retrodialysis samples were analysed by a vali-
dated HPLC assay [27].
Noncompartmental Analysis
NCA was performed in PKanalix (Monolix Suite 2019R1,
Lixoft, France). The linear-up, log-down approach was
employed with uniform weighing for log-linear regression of
the terminal phase, which was evaluated via standard
goodness-of-fit plots (e.g. observed versus predicted dependent
variables, weighted residuals versus prediction/time).
Extrapolations were based on predicted last concentrations.
The impact of individual characteristics on PK parameters
obtained via NCA was evaluated by linear regression in R.
Nonlinear Mixed-Effects Modelling Analysis
In the NLME analysis via integral-CA and midpoint-CA,
candidate PK models with plasma data attributed to the cen-
tral compartment and target-site data attributed to central or
peripheral compartments were evaluated in the NLME mod-
elling software NONMEM v7.4.3 (Icon Development
Solutions, Ellicott City, MD, USA) accessed with PsN v4.8.1
[28] through Pirana v2.9.6 (Certara, Princeton, NJ, USA). R
v3.6.0 (R Foundation for Statistical Computing, Vienna,
Austria) was used for dataset preparation, model evaluation
and post-processing results. Intercompartmental flows and
elimination from the central compartment were assessed using
linear and nonlinear processes.
The following clinical and demographic characteristics were
considered biologically plausible to affect levofloxacin PK and
were tested for inclusion as continuous covariates on selected
model parameters: Age, creatinine clearance (CLCR) [29],
leukocyte blood concentration, C-reactive protein concentra-
tion, gamma-glutamyl transferase, alanine and aspartate ami-
notransferase, serum albumin concentration, as well as body
Table I Baseline characteristics in
the study populations Population Number of patients Percentage of patients
Soft tissue infection patients 8 20.5%
Coronary bypass surgery patients 12 30.8%
Lung surgery patients 5 12.8%
Healthy volunteers 7 17.9%
Septic patients 7 17.9%
Continuous patient characteristics Median 5th – 95th percentile
Age [y] 61 23–89
Weight [kg] 75 51–120
Height [m] 1.70 1.54–1.87
Serum albumin concentration [g/l] 22.4 18.0–57.0
Creatinine clearance [ml/min]* 82.1 37.3–146
C-reactive protein concentration [mg/l] 6.30 0.500–21.3
Leucocyte concentration [109 cells/l] 7.35 5.06–14.3
Categorical patient characteristics Number of patients Percentage of patients
Sex (male) 25 78.1%
*calculated via Cockcroft Gault formula
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height and weight including derived alternative body size
descriptors such as body mass index and lean body weight
determined according to [30]. Additionally, the impact of the
categorical covariates sex and disease type was tested.
Statistical comparisons between nested models with addi-
tional covariates were made using the likelihood ratio test
[31]. Model selection was further based on statistical signifi-
cance (p<0.05), plausibility and precision of parameter esti-
mates. NLME models were evaluated by standard goodness-
of-fit plots. The predictive model performance was assessed by
visual predictive checks (n = 1000); the uncertainty, bias
and robustness of parameter estimates were evaluated by
nonparametric bootstrap (n = 1000) [32]. A detailed de-
scription of considered model equations can be found in
the Supplementary information. Accordance in exposure
estimates obtained via NLME approaches and NCA was
evaluated by linear regression in R. To evaluate the ex-
tent of distribution into the target site, penetration indi-
ces were calculated as fAUCISF/fAUCplasma over time
for adipose and muscle tissue.
Probability of Target Attainment and Cumulative
Fraction of Response Analysis
Due to the usage of levofloxacin in the treatment of lung
infections, such as CAP [19, 20], the adequacy of levofloxacin
dosing regimens recommended for the treatment of CAP [21]
was evaluated by probability of target attainment (PTA) anal-
ysis, a pharmacometric tool aimed at optimising dosing regi-
mens of anti-infectives with the goal of improving therapeutic
outcome and preventing the emergence and spread of resis-
tance [33]. For this purpose, Monte Carlo simulations (n =
1000 per covariate combination) of levofloxacin concentra-
tion over time in plasma were performed for the integral-CA
and midpoint-CA models for different dosing regimens. To
cover a broad range of PK/PD targets and MIC values
reported for levofloxacin by the European Committee on
Antimicrobial Susceptibility Testing (EUCAST), PTA for
achieving the CAP-related PK/PD target fAUC0–24/
MIC≥34 [34] was calculated for MIC = 0.100–4.00 mg/
l [35]. A plasma protein binding of 31.0%, the average across
reported values, was selected for calculation of unbound levo-
floxacin concentrations [36–39]. PTA was calculated using
the percentage of the simulated individuals who were at or
above the PK/PD target at each MIC. A dosing regimen was
considered adequate if PTA≥90%.
The adequacy of levofloxacin dosing regimens was addi-
tionally evaluated against the most prevalent CAP-associated
pathogens (Haemophilus influenzae, Staphylococcus aureus and
Streptococcus pneumoniae) [35, 40]. For this purpose, the cumula-
tive fraction of response (CFR) according to [41] was calcu-
lated by multiplying PTA by the cumulative proportion of
bacterial isolates at each MIC from EUCAST (MIC =
0.001–512 mg/l).
To consider relevant dosing regimens for the treatment of
CAP, once- and twice-daily intravenous short-term (30 min)
infusions of 500 mg levofloxacin were evaluated [21].
Comparison of Analysis Approaches
To identify the most appropriate analysis approach for the
evaluation of microdialysis data the competing analysis
approaches were compared based on (i) precision (only
NLME modelling approaches) and plausibility of parameter
estimates and (ii) goodness-of-fit and predictive model perfor-
mance. Subsequently, the impact of the choice of the analysis
approach on (a) levofloxacin exposure and (b) PK/PD evalu-
ation of levofloxacin dosing regimens (only NLME modelling
approaches) was evaluated. As the applied approaches to eval-
uate PTA and CFR relied on estimates of interindividual var-
iability through Monte Carlo simulation, only integral-CA
and midpoint-CA, but not NCA, were compared.
RESULTS
Per individual on average (range) 13 plasma concentrations (3–
15, n = 39 individuals), 14 microdialysate collections in ISF of
adipose tissue (6–28, n= 28 individuals) and 11 in ISF ofmuscle
(6–12, n = 24 individuals) were obtained after the start of the
levofloxacin administration. The geometric mean and 10th–
90th percentiles of the maximum levofloxacin concentration
(Cmax) in plasma were 8.25 mg/l, 7.04–13.5 mg/l (Fig. 1b),
but observations at the end of the infusion were only available
for lung surgery patients (n = 5, 12.8% of all patients). The
geometric mean of Cmax in ISF of adipose tissue (4.65 mg/l,
7.50–23.0 mg/l) and muscle (4.83 mg/l, 1.52–11.1 mg/l) were
comparable and delayed in comparison to plasma
(tmax = 1.64 h, 0.796–11.4 h, and tmax = 3.48 h, 1.17–11.0 h,
respectively).
Precision and Plausibility of Parameter Estimates
While the NCA approach did not necessitate structural model
development, the same final PK model structure was identi-
fied for integral-CA and midpoint-CA: A mammillary four-
compartment model with clearance from the central compart-
ment (Fig. 2). Plasma concentrations were related to the cen-
tral compartment and target-site concentrations were attrib-
uted to distinct peripheral compartments.
Total volume of distribution (Vtot) differed between NCA
(Vtot,mean = 104 l, at steady-state) and population estimates
from the NLME approaches midpoint-CA (Vtot = 82.7 l)
and integral-CA (Vtot = 81.1 l, Table II). Both population
estimates of Vtot were in accordance with the NLME model
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Fig. 1 Individual observations (a) and geometric mean and geometric standard deviation (b) of levofloxacin concentrations over time in plasma (total) and ISF
(interstitial space fluid) of adipose tissue and muscle (both unbound)
Fig. 2 Schematic levofloxacin nonlinear mixed-effects models via midpoint-CA (dialysate-corrected mid-interval compartmental analysis; left) and integral-
CA model (dialysate-based integral compartmental analysis; right). Solid arrows indicate mass transfer, grey dotted arrows indicate covariate relationships and
bold grey arrows indicate input and scaling from the retrodialysis submodel. Eyes denote observations included in the model. Adi: adipose tissue, CA:
compartmental analysis, CL: clearance, CLCR: creatinine clearance, CISF: calculated interstitial space fluid concentration, CRD: retrodialysate concentration,
CRP: retroperfusate concentration, Ctot: total plasma concentration, CμD: unbound microdialysate concentration, mus: muscle, Q: intercompartmental flow,
RR: relative recovery, V: volume of distribution
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based on plasma concentrations only (Vtot = 86 l, Tab. AI).
However, compared to the central volume of distribution (V1)
in integral-CA and the plasma only model (15.5 l and 21.7 l,
respectively), V1 was largely decreased inmidpoint-CA (4.82 l,
Tab. AII). Clearance obtained from all three approaches
(7.35–8.26 l/h) was comparable.
Volumes of distribution associated with ISF of adipose
tissue and muscle and the sum of intercompartmental
flows were comparable between midpoint-CA and
integral-CA (Table II). In contrast, ratios of rate constants
into and from the target site were similar for ISF of adi-
pose tissue (1.51 for midpoint-CA and 2.14 for integral-




(midpoint-CA) and the dialysate-
based integral compartmental anal-
ysis (integral-CA)
NCA Midpoint-CA Integral-CA
Structural model – 4 compartment mammillary 4 compartment mammillary
Structural PK parameters
Vtot [l] 104 82.7 81.1
CL [l/h] 8.26 7.35 7.78
Qtot [l/h] – 115 97.6
Adipose tissue k13/k31 – 1.51 2.14
Muscle k14/k41 – 4.44 1.03
Impact influential patient characteristics
CL-CLCR [(ml/min)−1] a 0.90%1 1.26%2 1.12%2
CLsepsis
b −45.5%1 −52.8%2 −43.4%2
Qadi-albumin [(g/l)
-1] c – 8.19%2 7.25%2
Stochastic parameters
IIV (range) – 46.5%CV-143%CV 26.4%CV-72.6%CV
RR related variability (adipose/muscle) – – 40.1%CV/50.3%CV
Residual variability – 30.3%CV3 8.83%CV-28.3%CV4
1 Estimated via linear regression of CL versus CLCR centred on median and separate intercepts for sepsis patients and
patients without sepsis. 2 Estimated via linear/categorical parameter-covariate relationships. 3 Single residual variability
term for all biological matrices. 4 Separate residual variability terms for all biological matrices. a Change of clearance per
ml/min deviation of CLCR from 82.1ml/min. b Change of clearance in patients with sepsis compared to patients without
sepsis. c Change of Qadi per g/l deviation of serum albumin concentration from 22.4 g/l.
CL: clearance, CLCR: creatinine clearance, CV: coefficient of variation, IIV: interindividual variability, k13: transfer rate
constant from central to adipose interstitial space fluid compartment, k14: rate constant from central to muscle compart-
ment, k31: rate constant from adipose tissue compartment to central compartment, k41: rate constant from muscle
compartment to central compartment, Qtot: sum of intercompartmental flows, Qadi: intercompartmental flow between
central compartment and adipose tissue compartment, Vtot: total volume of distribution, RR: relative recovery
Table III Summary of perfor-
mance evaluation of noncompart-
mental analysis (NCA), dialysate-
corrected mid-interval compart-
mental analysis (midpoint-CA) and
the dialysate-based integral com-
partmental analysis (integral-CA)
Evaluation criteria NCA Midpoint-CA Integral-CA
Computational time1 short (<2.00 s) medium (1150 s) long (24000 s)
Precision of PK parameter estimates2 n.a. – +
Goodness-of-fit3 (+)* – +
Predictive PK model performance4 n.a. – +
Differentiation between microdialysis technique-
and PK-related variability
– – +
Plausibility of penetration indices (fAUCISF/fAUCplasma) – + +
1CPU time on a 360 GHz Intel Core i7–7700
2 Relative standard error of key pharmacokinetic parameters from bootstrap <50%
3 Visual inspection of trends in standard goodness-of-fit plots
4 Assessed via visual predictive checks
*Limited to terminal phase of levofloxacin concentration-time profile
-: inadequate result/unapt; +: optimal result/apt; fAUC: area under the unbound concentration-time curve; ISF: inter-
stitial space fluid; n.a.: not applicable; PK: pharmacokinetic
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CA) but differed largely for muscle (4.44 for midpoint-CA
and 1.03 for integral-CA).
Identical relationships between PK parameters and patient
characteristics were identified for the three approaches:
Clearance increased by 9.00%–12.6% for each 10 ml/min
increase of CLCR (Table II), and was reduced by 43.4%–
52.8% in sepsis patients. The intercompartmental flow (not
available for NCA due to the lack of mass transfer
descriptions) associated with ISF of adipose tissue increased
by 7.25%–8.19% for each g/l increase in serum albumin con-
centration. The inclusion of these covariate relationships de-
creased the overall interindividual variability in the NLME
models substantially (relative reduction of coefficient of varia-
tion ≤30.1% for midpoint-CA and ≤43.7% for integral-CA).
On average, estimates of interindividual variability (not avail-
able for NCA) were higher in midpoint-CA versus integral-CA
Fig. 3 Visual predictive check (n =1000 simulations) for the dialysate-corrected mid-interval model “(midpoint-CA)” (a) and the dialysate-based integral
compartmental analysis “(integral-CA)” (b) for total plasma concentrations (1), microdialysate concentrations for ISF in adipose tissue (2) and ISF in muscle (3).
Circles: Observed levofloxacin concentrations; Lines: 5th, 95th percentile (dashed), 50th percentile (solid) of the observed (black) and simulated (grey) data. Shaded
areas: 95% confidence interval around 5th, 50th and 95th percentile of simulated data. μD: microdialysate; conc.: concentration; ISF: interstitial space fluid
Pharm Res (2021) 38:381–395 387
(Δ%CVmean = 27.1%). Only integral-CA allowed discrimina-
tion of residual variability attributed to microdialysis, retrodial-
ysis and plasma measurements (8.83%–28.3%CV, Tab. AII).
Here, residual variability on retrodialysis (18.4%–24.9%CV)
and microdialysis (25.4%–28.3%CV) was higher than for plas-
ma observations (8.83%CV).
Parameter precision of the structural parameter estimates
was comparable between midpoint-CA (relative standard error
(RSE): 10.9%–48.3%) and integral-CA (RSE: 3.89%–61.7%)
but parameter precision of interindividual variability of the key
PK parameters clearance and V1 was lower for midpoint-CA
(RSE: 62.5% and 71.2%, respectively) versus integral-CA
(RSE: 38.3% and 34.2%, respectively; Tab. AII), highlighting
an important advantage of integral-CA (Table III).
Goodness-of-Fit and Predictive Performance
of Nonlinear Mixed-Effects Modelling Approaches
In contrast to midpoint-CA, which demonstrated trends
indicating model overpredictions (plasma and adipose
tissue) and underpredictions (muscle) in the middle of
the measured concentration range (Fig. A1), no pro-
nounced trends were evident for integral-CA (Fig. A2),
showing superiority of integral-CA (Table III).
Fig. 4 Comparison of individual area under the levofloxacin concentration-time curves from 0 to 8 h (AUC0–8) and 0–24 h (AUC0–24) and maximum
concentration (Cmax) determined via noncompartmental analysis (NCA), dialysate-corrected mid-interval compartmental analysis (midpoint-CA) and dialysate-
based integral compartmental analysis (integral-CA). Plasma exposure (left column) is expressed as total and exposure in the interstitial space fluid (ISF) of
subcutaneous (s.c.) fat tissue (mid column) and in ISF of muscle tissue (right column) as unbound. Black line represents the median, grey lines connect exposure
metrics from the same individual, dark grey dots represent individuals with fraction of AUC extrapolated until infitiy>20%
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After accounting for interindividual differences in RR,
remaining differences between predicted retrodialysate
concentrations (used in integral-CA model to calculate
RR) and observed ones (used in midpoint-CA and NCA
to calculate RR) were evident (Fig. A2b2 and b4). This
divergence was quantified as residual unexplained variabil-
ity (Table AII).
Whereas all data points were evaluated in the NLME
approaches, NCA predictions were limited to the terminal
phase of the levofloxacin concentration-time profile in all ma-
trices employed for log-linear regression (Fig. A3).
In the visual predictive check of the integral-CA, themedian of
the simulated concentration-time profiles corresponded with the
median of the observed data of all matrices, whereas the 5th and
95th percentile of simulations were lower and higher, respectively,
than observed ones. Yet, observed percentiles lay within the 95%
confidence intervals of simulated ones, indicating an overall
good predictive model performance (Fig. 3b and Fig. A4). In
contrast, for midpoint-CA the 5th and 95th percentile of the
simulated concentration-time profile diverged from those of
observations for numerous sampling time points in plasma
and ISF of muscle (Fig. 3a), indicating over prediction of
Fig. 5 Levofloxacin total plasma concentration and unbound ISF (interstitial space fluid) concentrations over time for the dialysate-corrected mid-interval (light
grey) and the dialysate-based integral compartmental analysis (dark grey). Median (solid lines) and 95%CI (shaded bands) from 1000Monte-Carlo simulations are
shown. The non-species related resistance breakpoint in plasma (1 mg/l) is visualised as a dotted line
Fig. 6 Levofloxacin penetration
indices (ratios of unbound area
under the concentration-time pro-
files in plasma and target sites) for
ISF (interstitial space fluid) over time
for the dialysate-corrected mid-in-
terval (“midpoint-CA”, light grey)
and the dialysate-based integral
compartmental analysis (“integral-
CA”, dark grey). Median (solid lines)
and 95% CI (shaded bands) from
1000 Monte-Carlo simulations are
shown. Dots and whiskers show
median, 2.5th and 97.5th percentiles
of penetration indices calculated via
non-compartmental analysis
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PK-related variability. In addition, for ISF of muscle the
median simulated midpoint-CA profile indicated model
misspecifications. The less accurate predictive perfor-
mance compromised the applicability of midpoint-CA
for Monte Carlo simulations (Table III) and therefore
the subsequent PK/PD evaluation through PTA analysis.
Comparison of Levofloxacin Exposure
between Approaches
A comparison of individual exposure ranges determined via
NCA, midpoint-CA and integral-CA (Fig. 4a-b) revealed
differences in AUC from 0 to 8 h (AUC0–8) and AUC0–24 in
plasma between NCA (AUC0–8,range = 22.0–48.6 mg∙h/l,
AUC0–24,range = 34.1–114 mg∙h/l) and integral-CA (AUC0–
8,range = 22.8–57.1 mg∙h/l, AUC0–24,range = 34.7–112 mg∙h/
l), versus midpoint-CA (AUC0–8,range = 21.7–103 mg∙h/l,
AUC0–24,range = 33.1–173 mg∙h/l). This divergence of
midpoint-CA was further substantiated by the low concor-
dance (Lin’s concordance correlation coefficient ≤ 0.546) of
individual plasma AUC estimates between the midpoint-CA
versus integral-CA and NCA (Fig. A5-A6). The median plas-
ma Cmax (10.6 mg/l) was lower for NCA compared to
midpoint-CA (12.7 mg/l) and integral-CA (12.3 mg/l, Fig.
Fig. 7 Probability of target attainment (PTA) versus minimum inhibitory concentration (MIC) of dosing regimens for the treatment of community-acquired
pneumonia (CAP): 30-min 500 mg levofloxacin intravenous infusions once (q24h, a) and twice daily (q12h, b). PTA<90% (inadequacy of dosing regimen) is
shaded in grey. Vertical lines represent MIC values including epidemiological cut-off values of the CAP-related pathogens Staphylococcus aureus (MIC= 0.5 mg/l)
and Streptococcus pneumoniae (MIC= 2.0 mg/l). Differences in the evaluation of adequacy of dosing regimens between the dialysate-based integral compart-
mental analysis (integral-CA) and dialysate-corrected mid-interval compartmental analysis (midpoint-CA) at each MIC value are denoted as bold vertical lines. Inset
plots show complete PTA profiles versus MIC. CLCR: creatinine clearance
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A7), since for most individuals sampling times did not include
the end of the infusion (hence tmax was not covered), highlight-
ing a well-known inherent limitation of NCA versus NLME
approaches based on the sampling design.
Variability of individual AUC at target site was larger for
NCA (69.1%CV-79.2%CV) and midpoint-CA (52.3%CV-
56.0%CV) compared to integral-CA (32.6%CV-32.9%CV,
Fig. 4) and the accordance of estimates between the different
methods was low (Fig. A5-A7). By design, individual AUC
determined via NCA and midpoint-CA in both matrices was
dependent on RR, whereas no dependency was evident for
integral-CA (p = 0.0895 and p = 0.265, Fig. A8), highlighting
an advantage of integral-CA (Table III). Importantly, NCA
measures of AUC had a large proportion (>20% [42]) of
AUC extrapolated until infinity in plasma (45.7%), ISF of
adipose tissue (23.5%) and ISF of muscle (38.2%).
The larger variability associated with exposure simulations
from midpoint-CA compared to integral-CA led to broader
95% CI bands obtained from Monte Carlo simulations for all
three matrices (Fig. 5). The difference between rate constants
associated with ISF of muscle tissue estimated via midpoint-CA
and integral-CA manifested in differences in predicted Cmax
(Cmax,median = 5.38 mg/l versus 7.49 mg/l, respectively, Fig.
5c). Similarly, penetration indices (AUCISF/AUCplasma) were
relatively similar for both approaches for ISF of adipose tissue
but differed largely for muscle tissue (Fig. 6). Whereas penetra-
tion indices obtained from NLME approached 100% towards
the end of the sampling time, penetration indices obtained via
NCA yielded penetration indices>100% (Fig. 6). The implau-
sibility of penetration indices>100% indicated a further disad-
vantage of NCA (Table III).
Pharmacokinetic/Pharmacodynamic Evaluation
of Levofloxacin Dosing Regimens Based on Nonlinear
Mixed-Effects Modelling Approaches
Monte-Carlo simulations of levofloxacin plasma concentra-
tions following dosing regimens recommended for the treat-
ment of CAP (once- and twice-daily 500 mg levofloxacin
short-term infusions of 0.5 h [21]) were performed covering
the 5th to 95th percentile of study CLCR (37.3–146ml/min) of
individuals without sepsis.
Fig. 8 Cumulative fraction of response (CFR) versus creatinine clearance (CLCR) for 30-min 500 mg levofloxacin intravenous infusions once (a) and twice (b)
daily for the most relevant community-acquired pneumonia pathogens. CFR for the dialysate-based integral compartmental analysis is labelled black and CFR for
the dialysate-corrected mid-interval compartmental analysis is labelled grey. The dashed line denotes adequate coverage (≥90%)
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PTA was lower at higher CLCR and PTA calculated via
integral-CA (PTAintegral-CA) was higher than PTA determined
via midpoint-CA (PTAmidpoint-CA) when PTA≥90% (relevant
PTA range for the evaluation of adequacy of dosing regimens,
Fig. 7): For the epidemiological cut-off value (ECOFF) of
Staphylococcus aureus (MIC = 0.5 mg/l) the administration of
500 mg once-daily to an individual with healthy/elevated re-
nal function (CLCR= 146 ml/min) was only deemed ade-
quate via integral-CA but not midpoint-CA (Fig. 7a). The
same applied to the ECOFF of Streptococcus pneumoniae
(MIC = 2.0 mg/l) and the twice-daily administration of
500 mg levofloxacin to an individual with severe renal impair-
ment (CLCR= 37.3 ml/min, Fig. 7b). At low PTA (⪅50%),
midpoint-CA yielded larger PTA than integral-CA.
When considering species-specific MIC distributions via
CFR analysis of the most common CAP associated pathogens,
both NLME approaches evaluated the once-daily dosing reg-
imen as adequate to cover Haemophilus influenzae but not
Staphylococcus aureus (Fig. 8a). Adequate CFR to Streptococcus
pneumoniae for all investigated individuals was only achieved
by a twice-daily dosing regimen and for CLCR<146 ml/
min (Fig. 8b). Integral-CA showed higher CFR than
midpoint-CA for Streptococcus pneumoniae (up to 10.4% points).
DISCUSSION
Our study demonstrated inferiority of midpoint-CA andNCA
versus integral-CA to analyse clinical microdialysis PK data
(Table III), which resulted in inflated variability of exposure
estimates. As a result ~1/5 of penetration indices obtained
from NCA were >100%, which was implausible since levo-
floxacin (and other fluoroquinolones) demonstrated no accu-
mulation in the ISF [43]. Secondly, the evaluation of adequa-
cy of both levofloxacin dosing regimens employed for the
treatment of CAP for selected ECOFF via midpoint-CA was
erroneous in 1/3 patient cases. Thus, the observed pro-
nounced overestimation of variability in levofloxacin PK via
midpoint-CA had clinically relevant consequences on the
PK/PD evaluation of levofloxacin dosing regimens. Yet, no
clinically relevant differences in CFR calculated via the two
analysis approaches for CAP-related pathogens were evident.
Compared to midpoint-CA, estimates of interindividual
variability of integral-CA were lower, which can be explained
by the differentiation of the drug PK processes and micro-
dialysis associated variabilities through incorporation of RR
in the model, representing a key advantage of the integral-CA
approach. In the integral-CA, interindividual variability of
disposition-related parameters was determined independently
from variabilities of the microdialysis technique. This allowed
more reliable estimates of interindividual variability (as shown
in visual predictive checks) and covariate effects due to a re-
duced propensity of measurement technique-dependent
influences. Further illustration was provided by the lack of a
dependency of individual AUC estimates on RR.
In contrast to estimates of interindividual variability, levo-
floxacin plasma PK parameters were relatively similar for the
three analysis approaches. Vtot (NCA: 1.39 l/kg, midpoint-
CA: 1.10 l/kg, integral-CA: 1.08 l/kg) and clearance (NCA:
0.110 l/h/kg, midpoint-CA: 0.0980 l/h/kg, integral-CA:
0.104 l/h/kg) were in accordance with prior literature results
(0.800–1.50 l/kg for Vtot and 0.120–0.141 l/h/kg for clear-
ance) [39, 44–47], indicating robustness of estimates obtained
by either analysis approach.
Despite the general agreement of structural PK parameter
estimates between NLME modelling approaches and NCA,
the latter only allowed separate evaluation of the three avail-
able sources of observations (plasma, ISF in adipose tissue and
muscle), instead of accounting for mass transfer of levofloxacin
by integrating observations of plasma and target site simulta-
neously. This prevented the evaluation of the time scale of
equilibration of target sites with plasma, led to implausibly
high values of penetration indices above 100% at 24 h
(24.6%–188% for ISF in adipose tissue and 39.1%–508%
for ISF in muscle) and did not allow PK/PD evaluation
through Monte Carlo simulations, limiting the general appli-
cability of this approach.
Our findings on clinical relevance of the selected analysis
approach represented an expansion to the comparison for
preclinical microdialysis data provided by Tunblad et al.
[14], who reported results for the morphine model in rats.
To demonstrate how exposure differences can translate into
altered clinical evaluations of current dosing regimens based
on the selected analysis approach, we further included a com-
parison on the evaluation of dosing regimens via PTA and
CFR analysis. Tunblad et al. found only minor differences
in interindividual variability in PK parameters of midpoint-
CA and integral-CA, likely owing to the low variability of RR
in their study, which has been determined in a standardised
preclinical animal model under laboratory conditions
(14.0%CV) compared to our RR values determined in
patients in the clinic (41.0%CV-50.3%CV). With oftentimes
large variability of RR reported in the clinic [48, 49] the risk of
obtaining inflated estimates is high and thus the choice of a
suitable method to analyse microdialysis data is decisive.
PTA and CFR analysis were performed based on plasma
exposure since the currently employed PK/PD targets were
defined for AUC in plasma [34]. As indicated by levofloxacin
penetration indices≈1 at 24 h for both target sites, fAUC0–24
was similar in plasma and the target sites; hence results of PTA
in plasma and at target site would be similar as well. However,
the defined PK/PD targets might require revision, especially
with more abundant knowledge of drug concentration-time
profiles at target site instead of plasma exposure alone.
The midpoint-CA approach relied on attribution of the cal-
culated ISF concentration to the mid of the collection interval
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length, whichmight be adequate given linear pharmacokinet-
ics and small changes in the concentrations over time in each
collection interval [14]. However, in case of longer collection
intervals, fast change of concentrations over time or non-
linear pharmacokinetics, larger errors of the time scale are
likely and biased parameter estimates might be obtained.
In general, which concentration reflects the “true” concen-
tration in the ISF hitherto cannot be conclusively clarified,
especially due to the lack of comparable, alternative measure-
ment methods for unbound concentration in the ISF. This
should be further evaluated via simulation-based studies.
Such investigations should focus on the impact of sampling
interval length inclusion of retrodialysis-related observations
in the model, variability in RR and pharmacokinetic drug
properties (e.g. time scale of distribution into target site) on
the bias of parameter estimates to derive general rules when
midpoint-CA and NCA are sufficient or the computationally
more expensive integral-CA is required.
In conclusion, although NCA, midpoint-CA and integral-
CA yielded similar and plausible structural PK parameter
estimates, yet when evaluating interindividual variabilities of
PK parameters, only integral-CA allowed adequate model
predictivity. This translated into clinically relevant differences
in the PK/PD evaluation of recommended dosing regimens of
levofloxacin for the treatment of CAP between midpoint-CA
and integral-CA, leading to a risk of incorrectly rejecting levo-
floxacin dosing regimens via midpoint-CA; i.e. not offering an
adequate therapy.
Employing this knowledge will enable more accurate pre-
dictions of PK variabilities in the clinic, which will ultimately
improve the understanding of drug target-site PK, in particu-
lar distribution into the target site, for therapeutic decision-
making.
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